PMID- 9768583
OWN - NLM
STAT- MEDLINE
DCOM- 19981105
LR  - 20190723
IS  - 0091-6749 (Print)
IS  - 0091-6749 (Linking)
VI  - 102
IP  - 3
DP  - 1998 Sep
TI  - Intravenous immunoglobulin inhibits IgE production in human B lymphocytes.
PG  - 421-7
AB  - BACKGROUND: Intravenous immunoglobulin (IVIG) is commonly used as both an 
      immune-enhancing and immune-modulating agent. Treatment with high doses of IVIG 
      diminishes IgE secretion in patients with severe steroid-dependent asthma. 
      OBJECTIVE: We studied the action of IVIG on IgE production in highly purified B 
      lymphocytes stimulated without additional T cells to determine the action of IVIG 
      on B lymphocytes. METHODS: Human B cells were purified from tonsils, and T 
      lymphocytes were removed by E-rosetting. B cells were cultured with IL-4 (400 
      U/mL) and anti-CD40 antibodies (1 microg/mL inverted question mark, with or without additional IVIG. 
      Cell proliferation was determined by 3[H]-thymidine uptake, and supernatant IgE 
      was determined by ELISA. Cell cycle analysis was performed by flow cytometry, and 
      IgE transcripts were measured by in situ hybridization. RESULTS: IVIG (5 mg/mL) 
      decreased B-cell proliferation in IL4/anti-CD40-stimulated B cells by an average 
      of 74% (+/-6%). Addition of IVIG up to 48 hours after initiation of cell culture 
      led to significant diminution of cell proliferation at 96 to 120 hours. This 
      effect was dose dependent, with 10 mg/mL being the most effective and doses under 
      0.1 mg/mL having minimal effect. IVIG diminished the number of stimulated cells 
      progressing in the cell cycle by 30%, and there was no difference in cell 
      viability between IVIG-treated and IVIG-untreated cells. The production of IgE in 
      culture by anti-CD40/IL4-stimulated B lymphocytes was curtailed by greater than 
      80% after addition of 5 mg/mL IVIG. This was associated with a decrease in IgE 
      (epsilon) transcripts in IVIG-treated cultures. CONCLUSION: These data indicate 
      that diminution of IgE production in anti-CD40/IL-4-stimulated B cells by IVIG is 
      due to inhibition of early events related to proliferation and progression in the 
      cell cycle.
FAU - Sigman, K
AU  - Sigman K
AD  - Division of Allergy and Clinical Immunology, Montreal Children's Hospital, the 
      McGill University/Montreal Children's Hospital Research Institute, Quebec, 
      Canada.
FAU - Ghibu, F
AU  - Ghibu F
FAU - Sommerville, W
AU  - Sommerville W
FAU - Toledano, B J
AU  - Toledano BJ
FAU - Bastein, Y
AU  - Bastein Y
FAU - Cameron, L
AU  - Cameron L
FAU - Hamid, Q A
AU  - Hamid QA
FAU - Mazer, B
AU  - Mazer B
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Allergy Clin Immunol
JT  - The Journal of allergy and clinical immunology
JID - 1275002
RN  - 0 (Immunoglobulin Isotypes)
RN  - 0 (Immunoglobulin M)
RN  - 0 (Immunoglobulins, Intravenous)
RN  - 0 (RNA, Messenger)
RN  - 207137-56-2 (Interleukin-4)
RN  - 37341-29-0 (Immunoglobulin E)
SB  - IM
MH  - Apoptosis/drug effects
MH  - B-Lymphocytes/cytology/*drug effects/*metabolism
MH  - Cell Cycle/drug effects
MH  - Cell Division/drug effects
MH  - Cells, Cultured
MH  - Humans
MH  - Immunoglobulin E/*biosynthesis/physiology
MH  - Immunoglobulin Isotypes/drug effects
MH  - Immunoglobulin M/biosynthesis
MH  - Immunoglobulins, Intravenous/*pharmacology
MH  - Interleukin-4/pharmacology
MH  - Lymphocyte Activation
MH  - RNA, Messenger/metabolism
MH  - Stimulation, Chemical
EDAT- 1998/10/13 00:00
MHDA- 1998/10/13 00:01
CRDT- 1998/10/13 00:00
PHST- 1998/10/13 00:00 [pubmed]
PHST- 1998/10/13 00:01 [medline]
PHST- 1998/10/13 00:00 [entrez]
AID - S009167499800308X [pii]
AID - 10.1016/s0091-6749(98)70130-7 [doi]
PST - ppublish
SO  - J Allergy Clin Immunol. 1998 Sep;102(3):421-7. doi: 
      10.1016/s0091-6749(98)70130-7.